KALA BIO
KALA
13 hedge funds and large institutions have $4.81M invested in KALA BIO in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
6.38% less ownership
Funds ownership: 22.12% → 15.74% (-6.4%)
19% less funds holding
Funds holding: 16 → 13 (-3)
55% less capital inflows, than outflows
Capital inflows: $1.65M | Capital outflows: $3.63M
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $361K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$288K |
| 3 |
BlackRock
New York
|
+$105K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$26.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Clear Street
New York
|
-$1.88M |
| 2 |
Renaissance Technologies
New York
|
-$404K |
| 3 |
State Street
Boston,
Massachusetts
|
-$381K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$340K |
| 5 |
Two Sigma Securities
New York
|
-$249K |
KALA Hedge Fund Activity: Q1 2023 in Review
13 of the 6,291 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q1 2023, worth a combined $4.81M — down 63% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of KALA and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, adding an estimated $1.2M. The largest seller was Clear Street, exiting entirely with an estimated $1.88M sold.
- 13 institutional investors held KALA BIO (KALA) as of Q1 2023, down from 16 in Q4 2022.
- Funds reported $4.81M of KALA BIO stock for Q1 2023, down 63% quarter-over-quarter.
- 2 funds opened new KALA BIO positions in Q1 2023 and 5 closed out, a net change of -3 holders.
- The largest KALA BIO buyer in Q1 2023 was Millennium Management, an estimated $1.2M added.
- The largest KALA BIO seller in Q1 2023 was Clear Street, an estimated $1.88M sold.
Based on aggregated 13F filings for Q1 2023.